<DOC>
	<DOCNO>NCT00023790</DOCNO>
	<brief_summary>RATIONALE : Photodynamic therapy use light drug make cancer cell sensitive light kill tumor cell . This may effective treatment skin cancer cancer metastatic skin . PURPOSE : Phase I trial study effectiveness photodynamic therapy treat patient either squamous cell basal cell carcinoma skin solid tumor metastatic skin .</brief_summary>
	<brief_title>Photodynamic Therapy Treating Patients With Skin Cancer Solid Tumors Metastatic Skin</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose ( MTD ) silicon phthalocyanine 4 ( Pc 4 ) administer fix dose light patient advance cutaneous malignancy . - Determine MTD light administer fix dose study drug patient . - Determine pharmacokinetics Pc 4 patient . - Determine clinical antitumor response patient treat regimen . OUTLINE : This dose-escalation study . Patients receive silicon phthalocyanine 4 ( Pc 4 ) IV 2 hour day 1 follow light therapy 30-60 minute day 2 . Treatment repeat 6 week total 2 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos Pc 4 fix dose light maximum tolerate dose ( MTD ) Pc 4 determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Once MTD Pc 4 determine , additional patient treat fix dose Pc 4 ( 2 dose level MTD ) escalate dos light MTD determine . The MTD light define . Patients follow 6 week ( 8 week treat lesion lower extremity heal ) every 3 month thereafter . PROJECTED ACCRUAL : A total 25-30 patient accrue study annually .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Skin Neoplasms</mesh_term>
	<mesh_term>Silicon phthalocyanine</mesh_term>
	<mesh_term>Silicon</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm tumor potential curative therapy exists ( e.g. , surgery , radiotherapy , systemic chemotherapy ) The following tumor type eligible : Cutaneous nodular metastatic breast carcinoma lesion locoregional cutaneous , soft tissue , chest wall involvement No chest wall recurrence without prior radiotherapy Other metastatic site allow provided patient concurrently receive hormonal therapy trastuzumab ( Herceptin ) least 4 week duration Cutaneous superficial subcutaneous nodular metastatic head neck lesion Cutaneous nodular Kaposi 's sarcoma lesion Stage IAIIB IVA cutaneous Tcell lymphoma ( CTCL ) CTCL patch , plaque , tumor surface area 25 cm^2 area involve skin block therapy Squamous cell basal cell carcinoma skin eligible standard therapy ( e.g. , cryosurgery , radiotherapy , electrodesiccation curettage , excision ) Cutaneous subcutaneous metastasis solid tumor ( e.g. , thoracic , gastrointestinal , genitourinary cancer sarcomas ) Bidimensionally measurable disease No 2 lesion may treat No single area great 36 cm^2 may treat ( maximum 25 cm^2 tumor mass 1 cm margin ) Tumor treatable surface ( noncontact ) light illumination Skin type IIII No tumor eyelids Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : 18 Sex : Male female Menopausal status : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Hemoglobin least 9 g/dL Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL AST/ALT great 2 time upper limit normal ( ULN ) Alkaline phosphatase great 2 time ULN No history hepatic cirrhosis No hepatic disease require therapy Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance least 50 mL/min No renal disease require therapy Cardiovascular : No myocardial infarction within past 6 month No significant congestive heart failure require therapy No peripheral vascular disease Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Antinuclear antibody negative No sepsis No prior allergic hypersensitivity reaction paclitaxel vehicle No know photosensitivity diseases porphyria , systemic lupus erythematosus , xeroderma pigmentosum , polymorphous light eruption No symptomatic collagen vascular disease Insulindependent adultonset diabetes mellitus allow provide low extremity lesion PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 4 week since prior immunotherapy No concurrent immunotherapy Chemotherapy : See Disease Characteristics At least 4 week since prior systemic chemotherapy No concurrent chemotherapy Endocrine therapy : See Disease Characteristics No concurrent corticosteroid Radiotherapy : See Disease Characteristics More 4 week since prior radiotherapy More 4 week since prior ultraviolet B light therapy psoralenultraviolet light therapy nonstudy lesions/areas No concurrent radiotherapy Surgery : See Disease Characteristics Other : At least 5 day since prior warfarin At least 4 week since prior investigational drug At least 4 week since prior local therapy study lesion At least 6 month since prior photodynamic therapy No concurrent aspirin , aspirincontaining medication , nonsteroidal antiinflammatory drug ( e.g. , ibuprofen , indomethacin , cyclooxygenase [ COX ] 1 COX2 inhibitor ) No concurrent photosensitize medication tetracycline , psoralens , nalidixic acid , griseofulvin , sulfa drug , hydrochlorothiazide , furosemide , phenothiazine , amiodarone No concurrent therapeutic dosage warfarin ( nontherapeutic dosage allow )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>basal cell carcinoma skin</keyword>
	<keyword>squamous cell carcinoma skin</keyword>
	<keyword>recurrent skin cancer</keyword>
	<keyword>classic Kaposi sarcoma</keyword>
	<keyword>immunosuppressive treatment relate Kaposi sarcoma</keyword>
	<keyword>AIDS-related Kaposi sarcoma</keyword>
	<keyword>recurrent Kaposi sarcoma</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV basal cell carcinoma lip</keyword>
	<keyword>stage IV verrucous carcinoma oral cavity</keyword>
	<keyword>stage IV mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>stage IV adenoid cystic carcinoma oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent basal cell carcinoma lip</keyword>
	<keyword>recurrent verrucous carcinoma oral cavity</keyword>
	<keyword>recurrent mucoepidermoid carcinoma oral cavity</keyword>
	<keyword>recurrent adenoid cystic carcinoma oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV lymphoepithelioma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent lymphoepithelioma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>stage IV verrucous carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>recurrent verrucous carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent invert papilloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent midline lethal granuloma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent esthesioneuroblastoma paranasal sinus nasal cavity</keyword>
	<keyword>skin metastasis</keyword>
	<keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
	<keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>male breast cancer</keyword>
</DOC>